Pharmaceuticals & Biopharmaceuticals

Gothenburg – – September 08, 2026 -- Zinzino AB reported group revenue of SEK 282.2 million for August 2026, up 15% from SEK 245.9 million a year earlier, as growth in its direct-sales markets offset a sharp decline at subsidiary Faun Pharma.

Sales markets revenue climbs 16% to SEK 280.9 million in August

Zinzino's core direct-sales business generated SEK 280.9 million in August 2026, up from SEK 242.5 million in the same month last year, a 16% increase that drove the bulk of the group's top-line expansion.

Faun Pharma external sales drop to SEK 1.3 million from SEK 3.4 million

Faun Pharma's external sales fell to SEK 1.3 million in August 2026, down from SEK 3.4 million a year earlier, a decline that partially offset the stronger performance of Zinzino's sales markets and reduced the group's overall growth rate to 15% from the 16% posted by the sales markets alone.

Valby, Denmark – September 08, 2026 -- Lundbeck will present preclinical data at the European Epilepsy Congress in Athens showing its investigational drug bexicaserin simultaneously increases inhibitory and decreases excitatory neuronal activity in hippocampal brain tissue, a dual mechanism the company says supports broad-spectrum antiseizure potential across multiple epilepsy types.

Preclinical study links dual mode of action to broader seizure control

Cambridge – September 08, 2026 -- Insilico Medicine (HKEX: 3696) will join the HKEX Tech 100 Index effective September 08, 2026, following methodology changes announced September 08, 2026, that widen the benchmark's exposure to the AI value chain. Index changes take effect after market close on September 08, 2026 (Friday).

HKEX Tech 100 Index tracks 100 leading Hong Kong tech names across six themes

The index measures 100 of the largest Hong Kong-listed companies with high exposure to technology themes eligible for Southbound Stock Connect. It spans artificial intelligence, biotech and pharmaceutical, electric vehicles and smart driving, information technology, internet, and robotics.

Hong Kong – September 08, 2026 -- Akeso, Inc. (9926.HK) said its bispecific antibody ivonescimab produced a statistically significant and clinically meaningful overall survival benefit versus Merck's pembrolizumab in a pre-specified interim analysis of the Phase III HARMONi-2 trial, as assessed by an Independent Data Monitoring Committee.

Ivonescimab clears key secondary survival endpoint against Keytruda

The HARMONi-2 (AK112-303) study is a randomized, double-blind, multicenter registrational trial testing ivonescimab against pembrolizumab as first-line therapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors express PD-L1 at a TPS of 1% or higher. Detailed interim overall survival data will be presented at an upcoming international medical conference and published in a peer-reviewed journal.

Baltimore – September 08, 2026 -- Nanochon, Inc. has completed the first procedure in its First-in-Human clinical study for ChondrograftTM, a 3D-printed implant targeting articular cartilage defects of the knee, with the surgery performed at The Panama Clinic in Panama City.

Drs. Osorio and Tufiño perform first Chondrograft implant procedure in Panama

Dr. Juan Osorio, the study's Principal Investigator, and Dr. Emilio Tufiño, both specialists in regenerative sports medicine, carried out the bone-sparing, minimally invasive procedure. Dr. Tufiño noted the dedicated instrumentation set made the operation simple and efficient.

Thousand Oaks, Calif. – September 08, 2026 -- Amgen (NASDAQ: AMGN) will present at the 2026 Wells Fargo Healthcare Conference at 11:00 a.m. ET on Thursday, September 08, 2026.

Amgen's CFO and top medical and marketing executives will address investors

Thomas Dittrich, executive vice president and chief financial officer, Paul Burton, M.D., Ph.D., senior vice president and chief medical officer, and Kave Niksefat, senior vice president of Global Marketing and Access, will represent Amgen at the conference.

Webcast access will be public and archived for 90 days

The presentation will be webcast live and made available to media, investors and the general public via Amgen's website under the Investors section. Presentation times and webcast links are listed on Amgen's Investor Relations Events Calendar. The webcast will remain archived for replay for at least 90 days following the event.

Berlin – September 08, 2026 -- Germany's largest pharmaceutical trade association, Pharma Deutschland, has warned that new cost-containment measures under the GKV-BStabG threaten drug supply, innovation, and investment in the country, even as it welcomes a fresh round of government dialogue on AMNOG reform.

Federal Ministry convenes stakeholders for September 3 dialogue

The Federal Ministry of Health has invited industry representatives to an in-depth discussion on Thursday, September 08, 2026, focused on harmonizing Germany's drug pricing and assessment framework. Pharma Deutschland, which represents roughly 400 member companies employing about 80,000 people in Germany, said it backs the continuation of the Pharma- und Medizintechnik Dialog but insists selective bureaucratic fixes cannot offset broader damage from recent legislation.

North Chicago, Ill. – September 08, 2026 -- Allergan Aesthetics, an AbbVie company, has released a global study of more than 12,000 beauty-involved consumers across nine markets showing a decisive shift away from one-time aesthetic procedures toward personalized, long-term treatment plans.

Global survey data points to a structural change in patient demand patterns

The Layered Beauty: The New Aesthetic Mindset report, based on the 12,000-consumer dataset combined with practitioner input and regional analysis, finds patients increasingly expect multimodal treatment strategies that evolve with their goals and life stages rather than single-session fixes.

Skin quality now anchors broader aesthetic and wellness spending

Respondents identified skin quality as the foundation of aesthetic care, integrating treatments into wider beauty and wellness routines rather than treating them as isolated interventions.

Daejeon – – September 08, 2026 -- Alteogen Inc. (KOSDAQ: 196170) has signed an option and license agreement with Novartis worth up to US$3,223 million, granting the Swiss drugmaker rights to develop subcutaneous formulations for multiple Novartis products using Alteogen's ALT-B4 hyaluronidase.

Novartis secures multi-product option rights to ALT-B4 technology

Under the agreement, Novartis will hold multiple options to obtain exclusive rights to develop and commercialize subcutaneous formulations for several of its products using ALT-B4 (berahyaluronidase alfa). The enzyme, built on Alteogen's proprietary Hybrozyme platform, converts biologics normally delivered via intravenous infusion into faster, more convenient subcutaneous injections by temporarily depolymerizing hyaluronan in the extracellular matrix.

Hod Hasharon, Israel & Shanghai – September 08, 2026 -- Raziel Therapeutics and Fosun Pharma reported that RZL-012, an injectable lipolytic drug for submental fat reduction, met every primary and secondary endpoint in a 480-patient Phase 3 trial in China, with the primary responder rate outperforming placebo by 30 percentage points after a single treatment cycle.

Pivotal China trial clears statistical bar with wide margin over placebo

The registration study, conducted with Fosun Pharma affiliate JuveStar, enrolled 360 patients on active treatment and 120 on placebo, evaluating efficacy 84 days after one treatment cycle. Results showed a decisive statistical advantage across all measured endpoints, according to the companies.